Since the first mouse clone was produced by somatic cell nuclear transfer, the success rate of cloning in mice has been extremely low. Some histone deacetylase inhibitors, such as trichostatin A and scriptaid, have improved the full-term development of mouse clones significantly, but the mechanisms allowing for this are unclear. Here, we found that two other specific inhibitors, suberoylanilide hydroxamic acid and oxamflatin, could also reduce the rate of apoptosis in blastocysts, improve the full-term development of cloned mice, and increase establishment of nuclear transfer-generated embryonic stem cell lines significantly without leading to obvious abnormalities. However, another inhibitor, valproic acid, could not improve cloning efficiency. Suberoylanilide hydroxamic acid, oxamflatin, trichostatin A, and scriptaid are inhibitors for classes I and IIa/b histone deacetylase, whereas valproic acid is an inhibitor for classes I and IIa, suggesting that inhibiting class IIb histone deacetylase is an important step for reprogramming mouse cloning efficiency.
INTRODUCTION
The success of animal cloning by somatic cell nuclear transfer (SCNT) gives promise to applications such as endangered species preservation, livestock propagation, and cell therapies for medical treatment [1, 2] . Although mammal cloning has been successfully developed over the last decade [1] , the success rate is extremely low, especially in mice [2] . There is a high incidence of developmental anomalies [3] such as placental overgrowth [4, 5] , obesity [6, 7] , umbilical hernias [8] , and neonatal death [9] . Various approaches have been used with the aim of improving the efficiency of SCNT cloning [8, 10] . These include changing the timing of activation of reconstructed oocytes [11, 12] , chemical treatment of donor cells before SCNT [13] , serial rounds of NT [14] , and cloneclone aggregation [15] . However, the current rate of full-term development of cloned mice is still very low compared with that of normally fertilized embryos.
Molecular analyses of cloned embryos or offspring revealed abnormal epigenetic modifications such as DNA methylation and histone modifications [16] [17] [18] [19] [20] [21] [22] [23] rather than genetic abnormalities per se, which suggests that epigenetic modifications might be a key factor for improving the cloning success rate. Therefore, the prevention of such epigenetic errors should lead to an improvement of the success rate in animal cloning. Recently, our laboratory [24, 25] and Rybouchkin et al. [26] reported that treatment of SCNTgenerated mouse embryos with trichostatin A (TSA), a histone deacetylase inhibitor (HDACi), improved the full-term development of B6D2F1 strain cloned mice and the rate of establishing NT-generated embryonic stem (ntES) cell lines. More recently, the treatment of SCNT-generated embryos with scriptaid, an HDACi with low toxicity that enhances transcriptional activity and protein expression in cells [27] , significantly enhanced the cloning efficiency of inbred mouse strains [28] and miniature pigs [29] . On the other hand, another HDACi, aroyl pyrrolyl hydroxamide (APHA), did not show any positive effects [28] , and the HDACi sirtinol showed little effect on mouse cloning efficiency [30] . Although the mechanism underlying the improvement in quality of cloned mouse embryos resulting from treatment with HDACi's remains unknown, we recently found that TSA treatment caused an increase in not only histone acetylation but also in chromosome decondensation and in the levels of newly synthesized RNA in 2-cell cloned embryos [31] . It has been demonstrated that some kind of HDACi enhances somatic cell genomic reprogramming and positively modifies epigenetic abnormalities, such as the acetylation of histones H3K9 and H3K14 [23] .
In general, HDACs are divided into five categories: class I (HDAC 1-3 and 8), class IIa (HDAC 4, 5, 7, and 9), class IIb (HDAC 6 and 10), class III (SIRT 1-7), and class IV (HDAC 11) [32] . The HDACs are generally expressed in almost all tissues and appear to be key enzymes in the regulation of gene expression, but the expression level of various HDACs was different within different tissue types [33] . However, HDACi's have been shown to induce specific changes in gene expression and to influence a variety of other processes, including growth arrest, differentiation, cytotoxicity, and induction of apoptosis. Therefore, although it is obvious that some HDACi's could enhance nuclear reprogramming, they may at the same time cause damage to the embryo. Thus, inhibition of a particular class of HDAC to avoid the side effect of HDACi toxicity is probably important for improving cloning efficiency and for modifying aberrant genomic reprogramming.
Scriptaid and TSA can inhibit classes I and IIa/b HDACs [32, [34] [35] [36] [37] , whereas APHA can inhibit classes I and IIa/b but especially HDAC3 and HDAC6, compared with other HDACs [32, 38] . Sirtinol can inhibit class III HDAC. In this study, to determine the best HDACi and/or type of HDAC responsible for improving reprogramming efficiency, we chose three other HDACi's: suberoylanilide hydroxamic acid (SAHA or vorinostat) and oxamflatin, which inhibit classes I and IIa/b, as does TSA [32, 34-36, 39, 40] , and valproic acid (VPA) that inhibits classes I and IIa [34] . Our results revealed that SAHA and oxamflatin treatments produced significant improvements in the full-term development of cloned mice and ntES cell line derivation. However, although VPA was reported to increase the reprogramming efficiency of mouse fibroblasts by more than 100-fold to establish induced pluripotent stem cells [41] , it had no effect on the success rate of mouse cloning.
MATERIALS AND METHODS

Animals
B6D2F1 (C57BL/6 3 DBA/2) strain female mice were used for oocyte production and as somatic cell donors. In addition, the BD129F1 (B6D2F1 3 129/Sv) strain was also used for donor cells. Surrogate mothers were pseudopregnant ICR females that mated with vasectomized males of the same strain. B6D2F1 and ICR strains of mice were purchased from Shizuoka Laboratory Animal Center (Hamamatsu, Japan), and the BD129F1 mice were produced by our institute. All animal experiments conformed to the Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Committee of Laboratory Animal Experimentation of the RIKEN Kobe Institute.
Collection of Oocytes
Mature B6D2F1 female mice were superovulated by an i.p. injection of 5 IU pregnant mare serum gonadotropin (Teikokuzoki Co., Tokyo, Japan) and 5 IU human chorionic gonadotropin (hCG; Teikokuzoki Co.) at 48-h intervals. Cumulus-oocyte complex were collected from the oviducts about 16 h after hCG injection and treated with 0.1% hyaluronidase (Sigma-Aldrich, St. Louis, MO) in drops of Hepes-buffered CZB medium (HEPES-CZB) until the cumulus cells had dispersed. The oocytes were transferred to fresh droplets of HEPES-CZB and denuded of almost all cumulus cells by gentle pipetting.
Oocytes showing homogeneous ooplasm were selected and cultured in new drops of KSOM (KSOMaa; Specialty Media Inc., Phillipsburg, NJ) medium containing nonessential and essential amino acids covered with mineral oil at 378C in an atmosphere of 5% CO 2 in air until use.
Preparation of TSA, SAHA, Oxamflatin, and VPA TSA (Sigma-Aldrich), SAHA (Cayman Chemical Company, Ann Arbor, MI), and oxamflatin (Sigma-Aldrich) were dissolved in dimethyl sulfoxide (DMSO), prepared as 2003 stock solutions, and stored at À208C. VPA (SigmaAldrich) was dissolved in distilled water as a 1003 stock solution and stored at room temperature. These were added to the activation or culture media at 1:200 or 1:100 dilutions according to each experiment's protocol. For the control and VPA groups, DMSO was added to the culture medium at the same concentration as used in other treatments.
Production of Embryos by Intracytoplasmic Sperm Injection and SCNT
Intracytoplasmic sperm injection (ICSI) was performed as described [42] . One microliter of the sperm suspension incubated at 378C for 30 min was mixed with a 20-ll drop of HEPES-CZB containing 10% (w/v) polyvinylpyrrolidone (PVP; Irvine Scientific, Santa Ana, CA). The sperm head was separated from the tail by the application of several piezo pulses, and the head was then injected into the oocyte. After 10 min of recovery at room temperature, the oocytes were cultured in KSOM medium for preimplantation development.
Nuclear transfer was performed as described [2, 43] . Enucleated B6D2F1 oocytes were injected individually with a cumulus cell nucleus. After nuclear transfer, the reconstructed oocytes were activated using 10 mM SrCl 2 in Ca 2þ -free CZB medium in the presence of 5 lg/ml cytochalasin B supplemented with TSA (50 nM), SAHA (0.1, 1, 10, or 100 lM), oxamflatin (0.01, 0.1, 1, or 10 lM), or VPA (0.02, 0.2, 2, or 20 mM) for 6 h. Oocytes were then cultured in KSOM with all treatments at the same concentrations as above for a further 3 h. After three washes in KSOM, cloned embryos were cultured in the same medium for development. Usually, one droplet (10-15 ll) contained about 20 embryos and was cultured without change of medium until the end of the experiment. The preimplantation developmental rates of cloned embryos were examined from the pronuclear to the expanded blastocyst stage (96 h after activation). To produce offspring, 2-cell embryos were transferred into the oviducts of pseudopregnant ICR females at 0.5 days postcoitus (dpc) with vasectomized males, and any offspring were obtained at 19.5 dpc by cesarean delivery.
Establishment of ntES Cell Lines
Cloned embryos were produced as described above, and when they reached the blastocyst stage they were used to establish ntES cell lines as described [14, [44] [45] [46] . When the inner cell masses (ICMs) were growing normally and had been passaged five to six times, they formed ES cell-like colonies, and cell numbers were expanded in six-well dishes (9.6 cm 2 ). At this time, we judged 
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these cells to be established, and all cell lines were examined by alkaline phosphatase staining. In addition, we selected two to three cell lines at random and examined these further by immunostaining to determine their pluripotency.
Immunofluorescence and Alkaline Phosphatase Staining
The cell numbers in blastocysts were estimated by counting the total number of nuclei and the number of trophectoderm (TE) nuclei using 4,6-diamidino-2-phenylindole (DAPI) staining and immunostaining for CDX2, respectively. The cell number of the ICM was estimated as the total number of nuclei minus the number of TE nuclei. Immunofluorescence staining of cloned blastocyst and ntES cells was performed as previously described [47] [48] [49] . For immunostaining of blastocysts, the primary antibody used was an anti-CDX2 mouse monoclonal antibody (1:200; BioGenex, Inc., San Ramon, CA) for detecting the TE, and the secondary antibody was Alexa Fluor 488-labeled goat anti-mouse IgG (Molecular Probes, Inc., Eugene, OR). DNA was stained with DAPI (2 mg/ml; Molecular Probes, Inc.).
For the TUNEL assay, blastocysts were collected at 96 h after activation, washed twice with PBS containing 0.5% PVP, and fixed with 4% paraformaldehyde-PBS (Wako, Osaka, Japan) for 30 min at ambient temperature. After washing, embryos were permeabilized in 0.375% Triton X-100 for 30 min. TUNEL analysis was performed using the fluorescein In Situ Cell Death Detection Kit (Roche, Boehringer-Mannheim, Germany) following the manufacturer's recommendations. After the TUNEL reaction, embryos were washed three times, blocked in 1% BSA-PVP, and immunostained for CDX2, and the nuclei were stained with DAPI.
For immunostaining of ntES cells, the primary antibodies used were mouse monoclonal anti-Oct3/4 (POU5F1; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or rabbit polyclonal anti-Nanog (ReproCELL Inc., Tokyo, Japan), and the secondary antibodies were Alexa Fluor 568-labeled goat anti-mouse IgG and Alexa Fluor 488-labeled goat anti-rabbit IgG (both from Molecular Probes). The chromosomes were stained with DAPI (2 lg/ml; Molecular Probes). Established ntES cell lines were also tested for pluripotency by alkaline phosphatase staining according to the manufacturer's protocol (Sigma-Aldrich).
Statistical Analysis
Outcomes were evaluated using chi-square tests, and P , 0.05 was regarded as statistically significant.
RESULTS
In Vitro Development of Cloned Embryos Following HDACi Treatment
To assess genomic reprogramming by HDACi's after SCNT (SAHA, oxamflatin, and VPA), we treated cloned embryos with different concentrations of these chemicals and examined the developmental rates in vitro from the pronuclear to the blastocyst stage at 96 h after oocyte activation. In the SAHAtreated group, cloned embryos treated with 1 lM showed the highest score (70% [76/108]), followed by 0. 
Full-Term Development of SCNT-Cloned Embryos Following SAHA or Oxamflatin Treatment
To test whether SAHA or oxamflatin treatment improved the in vivo development of cloned embryos, we transferred 2-cell cloned embryos derived from B6D2F1 cumulus cells into surrogate mothers. Based on the effects of SAHA and oxamflatin concentrations on in vitro development (Fig. 1, A  and B) , we decided to use 1 lM SAHA and 0.1 or 1 lM 
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oxamflatin for this experiment, as well as 50 nM TSA. In the SAHA-treated group, we obtained 12 healthy cloned offspring (9.4%) and often saw multiple conceptions. Similarly, when 1 lM oxamflatin was used, the cloning success rate increased significantly, up to 7.5%. Both groups showed significantly better offspring rates than the control (2.6%; Table 1 ). We also used cumulus cells from BD129F1 mice as NT donors, because we have found that the cloning success rate of this strain is higher than with the B6D2F1 strain (unpublished observations). When cloned embryos were treated with 50 nM TSA or 1 lM SAHA, 13 live offspring were obtained in both groups (16%; Table 2 ). However, the VPA-treated group did not show any significant difference from controls (7% and 8%, respectively; Table 2 ). These HDACi-treated cloned mice showed no overtly abnormal phenotypes, except for large placentas, and grew to adulthood normally, as with control clones.
Assessment of the Quality of HDACi-Treated Cloned Blastocysts by Immunostaining
To determine whether the improvements associated with a high birth rate were reflected in blastocyst quality, we counted total numbers of blastomere nuclei (DAPI staining), the expression pattern of markers for TE (CDX2 staining), and the estimated cell numbers in the ICM (total number of cells minus TE cells; Fig. 2 ). The total numbers of blastomeres and the number of TE cells in cloned blastocysts were slightly higher in the SAHA-and oxamflatin-treated group than in controls (Table 3) , whereas there were over twice as many ICM cells in SAHA-or oxamflatin-treated blastocysts compared 
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with controls (P , 0.05; Table 3 ). This result suggests that SAHA and oxamflatin might enhance the reprogramming of somatic cell nuclei and help increase ICM cell numbers in the preimplantation development of SCNT-generated clones.
Assessment of the Quality of HDACi-Treated Cloned Blastocysts by TUNEL Assay
As shown in Table 3 , the ICM cell numbers of SAHA-and oxamflatin-treated blastocysts were increased by an increase in the maximum rather than the minimum number of cells compared with the control. This may suggest that it is not the rate of cell division but rather the rate of cell death (apoptosis) that mediates the effect of HDAC inhibition. To determine whether the rate of apoptosis was reflected in blastocyst quality, we counted the total numbers of apoptotic cells by TUNEL assay and estimated the numbers of apoptotic cells in the TE and ICM by costaining with CDX2. In all experiments, most of the apoptotic cells were observed in ICM rather than in TE. The total numbers of apoptotic cells in cloned blastocysts were significantly lower in the TSA-, SAHA-, and oxamflatintreated groups than in the control (P , 0.05, Fig. 3) . However, INHIBITING CLASS IIb HDAC IMPROVES MOUSE CLONING although there was no significant difference between these groups, the VPA-treated embryos showed higher numbers of apoptotic cells than embryos treated with other HDACi's. This result suggests that TSA, SAHA, and oxamflatin improve the quality of the cloned embryo by reducing cell death in the ICM, whereas VPA could not prevent the appearance of apoptosis during embryo culture.
Establishment of ntES Cell Lines from SAHAor Oxamflatin-Treated Cloned Blastocysts
Finally, we attempted to establish ntES cell lines from SAHA-or oxamflatin-treated cloned blastocysts, because this approach has potential value for assisted animal reproduction, such as in the regeneration of extinct animals [50] . Consistent   FIG. 4 . Production of cloned mice and generation of ntES cells after SAHA treatment. A) Cloned mice from SCNT-generated embryos following treatment with SAHA showed no obvious abnormality with the exception of large placentas. B) Clones (black) derived from an SAHA-treated embryo nursed by a foster mother (white) grew to adulthood normally. C-F) ntES cell line derived from SAHA clone blastocysts. All cell lines were examined when cells were passaged five to six times. C) Alkaline phosphatase staining. D) DNA was stained blue with DAPI. E) Green immunostaining for NANOG. F) Red immunostaining for POU5F1. Original magnification x200. with the full-term development results for clones, the rates of establishing ntES cell lines from HDACi-treated cloned blastocysts were two to three times greater than from control clones (Table 4) , which is comparable to our previous studies [14, [44] [45] [46] . When we selected two or three ntES cell lines randomly and analyzed then by alkaline phosphatase and immunofluorescence staining for the ES cell-specific markers Oct3/4 and Nanog, all proved positive, as shown in Table 4 and Figure 4C -F.
DISCUSSION
To date, 18 HDACs have been identified in human cells, and these are subdivided into five classes based on their homology to yeast HDACs, subcellular localization, and enzymatic activities [32] . Class I HDACs displays high homology to the yeast RPD3 protein, are found preferentially in the nucleus, and are expressed ubiquitously throughout all human tissues. Class II HDACs share homology with the yeast Hda I protein and shuttle between the nucleus and the cytoplasm. This set is further divided into two subclasses, IIa and IIb. HDAC IIb differs from the other class II HDACs in that it has two deacetylase domains [51, 52] . The class III HDACs are homologs of the yeast SIR2 protein and require NAD þ for their activity. HDAC 11 is the only member of class IV and shares some sequence homologies with classes I and II. Classes I and II are zinc-dependent while class III is not [53, 54] .
As shown in Table 5 , so far seven HDACis have been examined in our laboratory. TSA, scriptaid, SAHA, and oxamflatin are inhibitors for class I and IIa/b HDACs and are categorized as hydroxamic acids [32, 34-37, 39, 40] . These significantly improved cloning efficiency (Tables 1 and 5 ). On the other hand, APHA is an inhibitor of class I and IIa/b HDACs but is .10-fold more active against HDAC 3 (class I) and HDAC 6 (class IIb) than the other HDACs [32, 38] . VPA is an inhibitor for classe I and IIa HDACs [34] . Those two HDACi's did not improve the cloning success rate at concentration ranges where they did not harm embryo development. The effects of sirtinol on the development of mouse clone embryos have been reported. This is an inhibitor for class III HDACs; however, the effect was very limited [30] . Thus, inhibition of class IIb HDACs, or most likely HDAC 10, by hydroxamic acids appears to be very important for improving the successful cloning of mice (Table 5 ). It is known that HDAC 6 preferentially targets not only histone deacetylase but also other substrates, including heat shock protein (HSP) 90 and a-tubulin [55, 56] . Though the function of HDAC 10 was not known for a long time, very recently, Lai et al. [57] discovered that HDAC 10 probably deacetylates HSP70 and relieves repression of melanogenesis. They concluded that HDAC 6 and HDAC 10 affect the acetylation status of molecular chaperones and influence their downstream activities, such as modulation of the action of nuclear hormone receptors and other regulatory proteins [57] . The relationship between these other pathways and embryo development is not clear, but it was found that the rate of apoptosis in mouse embryos could be relatively easily increased by such factors as different culture conditions [58] . Our data confirmed that the rate of apoptosis in cloned embryos was increased in control (without HDACi) and VPA-treated embryos, whereas treatment of embryos with other HDACi's reduced it to the level in the ICSI control (Fig. 3) . It is probable that these other pathways could have negative effects on embryo development or lead to complete genomic reprogramming following SCNT. Previous studies have shown that several HDACi's and a DNA methyltransferase inhibitor have modest effects on the efficiency of induced pluripotent stem (iPS) cell establishment from somatic cells using virally mediated transfection of four factors: POU5F1, KLF4, SOX2, and MYC [41] . Three HDACi's-TSA, SAHA, and VPA-or DNA methyltransferase inhibitor 5-azacytidine (5-azaC) greatly improved the reprogramming efficiency of somatic cells to iPS cells, and VPA was the most potent of these [41] . We previously speculated that reprogramming following SCNT might share common mechanisms with the viral induction of iPS cells. However, our results revealed that VPA could not improve the developmental capacity of cloned embryos, even during in vitro culture (Fig. 1C) . Huangfu et al. [41] reported that the effect of VPA on reprogramming may be a result of the collective effects of upregulation of ES-specific genes and downregulation of MEF-specific genes. Because iPS cells are pluripotent cells, it is probable that VPA is effective for induction of pluripotency in somatic cells. However, for animal cloning, somatic cell nuclei must first become totipotent and VPA may not support this induction.
Similarly to HDACis, DNA methyltransferase inhibitor could not improve the developmental capacity of cloned embryos [13, 59] , whereas the induction rate of iPS cells was improved. These results indicate that the reprogramming of somatic cell nuclei by oocyte cytoplasm might involve different mechanisms than those involved in iPS cell induction.
Why do cloned embryos require HDACi treatment for better genomic reprogramming? In nature, the oocyte cytoplasm contains reprogramming systems that convert the sperm and oocyte nuclei to a totipotent state, such as histone acetylation or DNA demethylation [23, 60, 61] . However, it is not yet clear whether these reprogramming factors are sufficient to reprogram the somatic cell nucleus, because the reprogramming factor of the oocyte cytoplasm is prepared for the receipt of a gametic nucleus, not a somatic cell nucleus. For example, when embryos produced by normal fertilization were treated with HDACi's, their developmental capacity was impaired [62, 63] . By contrast, in embryos produced by round spermatid microinjection [64] and in cloned embryos [24, 25, 28 ], HDACi's can significantly increase the potential for full term development. In general, it is considered that incomplete reprogramming of somatic cell nuclei following SCNT arises [30] from poor reprogramming in the oocyte. However, these lines of evidence suggest that the oocyte cytoplasm might reprogram the somatic cell nucleus too strongly, or that the somatic cell nucleus is more sensitive to oocyte reprogramming factors than gametic cell nuclei. Therefore, by inhibiting a particular HDAC-especially class IIb-during reprogramming, the donor nuclei in our study were possibly reprogrammed more correctly, resulting in a higher success rate for cloning. Consistent with these results, when large oocytes generated by fusion of two oocytes were used for nuclear transfer, no cloned offspring were obtained [65] . In that study, although the concentration of oocyte reprogramming factors was the same, the total amounts of factors were increased. However, increased amounts of factors may have a negative effect for somatic cell reprogramming. This also suggests that the ''too strong'' reprogramming potential of oocytes might impair the development of cloned embryos following SCNT. In conclusion, our data strongly suggest that HDACi treatment can be used not only in improving the success rate of animal cloning, but also in helping to identify the key molecular pathways of genomic reprogramming.
